Glenmark Pharmaceuticals Initiates Class II Recall of Diltiazem Hydrochloride Capsules Due to Dissolution Failure
Glenmark Pharmaceuticals Inc., USA has initiated a Class II recall for 6,528 bottles of Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, due to failed dissolution specifications. This nationwide recall, stemming from a long-term stability study, necessitates immediate action for procurement and supply chain leaders to mitigate disruption and ensure patient safety.
FDA Class II Recall: Dissolution Failure for Glenmark's Diltiazem Hydrochloride
Glenmark Pharmaceuticals Inc., USA has initiated a voluntary Class II recall for 6,528 bottles of Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg. This critical action, designated recall number D-0430-2024, commenced on March 26, 2024, following the discovery of out-of-specification (OOS) results in dissolution testing. Specifically, the product failed to meet dissolution specifications at the 12-month time point during a long-term stability study. For procurement directors and regulatory affairs heads, this means immediate attention to product quality and compliance is paramount. A Class II recall indicates that the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The affected lot, 17230304, carries an expiration date of December 31, 2024. This failure directly impacts the drug's ability to release its active ingredient effectively over time, potentially compromising therapeutic efficacy for patients relying on this medication for conditions such as hypertension and angina. Businesses must assess their exposure to this specific lot and understand the implications for patient outcomes and potential liability.
Glenmark Pharmaceuticals' Role and Product Scope in the Diltiazem Market
The recall involves Diltiazem Hydrochloride Extended-Release Capsules, USP 120 mg, a human prescription drug distributed nationwide in the United States. Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ, is the recalling firm, though the product itself is explicitly labeled as a "Product of India." This distinction is crucial for supply chain VPs, highlighting the complexities of global pharmaceutical manufacturing and distribution networks. The affected product is identified by NDCs 68462-562, 68462-850, and 68462-851, with specific package NDCs including 68462-562-01, 68462-850-01, and 68462-851-01. The application number associated with this product is ANDA212317. For business development executives, this event underscores the importance of robust quality agreements with overseas manufacturers and thorough due diligence on product stability data, particularly for extended-release formulations where consistent drug delivery over time is critical. The 6,528 bottles represent a tangible volume that needs to be accounted for, impacting inventory and sales projections for this specific generic offering.
Supply Chain and Procurement Impact: Navigating Diltiazem Hydrochloride Shortages
The nationwide distribution of 6,528 bottles of Glenmark's Diltiazem Hydrochloride Extended-Release Capsules means that procurement teams across the U.S. must immediately identify and quarantine affected stock. Supply chain VPs face the challenge of potential short-term supply disruptions for this specific dosage and formulation. While Diltiazem Hydrochloride is a widely available generic, a Class II recall of this magnitude for a specific manufacturer's lot can create localized or temporary shortages, particularly for healthcare providers and pharmacies that rely heavily on Glenmark as a supplier. This situation necessitates a rapid assessment of current inventory levels, re-evaluation of supplier diversification strategies, and potentially expedited qualification of alternative Diltiazem Hydrochloride suppliers. Regulatory affairs heads must ensure all recall procedures are meticulously followed, including notification to downstream customers and proper disposition of recalled product, to avoid further compliance issues. The financial implications extend beyond the cost of returned goods, encompassing potential lost sales, increased administrative burden, and reputational damage.
Broader Regulatory Context: FDA's Vigilance on Pharmaceutical Quality
This Glenmark recall occurs within a broader landscape of heightened FDA scrutiny over pharmaceutical quality and compliance. The agency's ongoing vigilance is evident in other recent actions, such as the Class II recall of Essential Wellness Pharma's Progesterone Injection for sterility assurance failures, and the FDA hearing concerning Amgen's Tavneos market future amidst independent data review. While these events are distinct from Glenmark's situation, they collectively signal an unwavering focus by the FDA on ensuring drug safety, efficacy, and manufacturing quality across the industry. For regulatory affairs heads, this reinforces the need for proactive and continuous monitoring of quality management systems, especially for complex formulations like extended-release capsules where dissolution profiles are critical for therapeutic performance. Business development executives should recognize that a strong compliance record is increasingly a competitive differentiator, as regulatory issues can severely impede market access and erode customer trust. This environment demands that all pharmaceutical companies, regardless of size or market share, maintain rigorous quality control protocols to withstand intense regulatory oversight.
Remediation Expectations and Future Regulatory Scrutiny for Glenmark
As a firm-initiated voluntary recall, Glenmark Pharmaceuticals Inc., USA is responsible for conducting a thorough investigation into the root cause of the failed dissolution specifications. This will involve scrutinizing their manufacturing processes, quality control procedures, and stability study protocols, particularly given the "Product of India" origin. For regulatory affairs and quality assurance teams, this means preparing a comprehensive corrective and preventive action (CAPA) plan to address the OOS finding and prevent recurrence. The ongoing status of the recall indicates that the FDA will be monitoring Glenmark's actions closely. While no prior FDA Warning Letters or Import Alerts are immediately evident from the provided context, repeated quality failures could escalate regulatory scrutiny, potentially leading to increased inspections, enforcement actions, or even an Import Alert on products from the originating manufacturing facility. Procurement directors should consider this potential for future regulatory action when evaluating Glenmark as a long-term supplier, understanding that unresolved quality issues can pose significant supply continuity risks. Proactive engagement with Glenmark on their remediation efforts will be crucial for managing future supply chain stability.